Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julius Strauss

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Current Oncology Reports|August 16, 2015
Integrating Immunotherapies in Prostate CancerJulius Strauss, Ravi A Madan
Expert Review of Vaccines|February 19, 2016
Therapeutic vaccines for prostate cancer: recent advances and future directionsJulius Strauss, Ravi A Madan
Anticancer Research|January 2, 2016
Using Epigenetic Therapy to Overcome Chemotherapy ResistanceJulius Strauss, William D Figg
Cancer Biology & Therapy|June 10, 2015
Evaluating immune responses after sipuleucel-T therapyJulius Strauss, Ravi A Madan, William D Figg
Expert Opinion on Biological Therapy|March 25, 2016
Considerations for the combination of anticancer vaccines and immune checkpoint inhibitorsJulius Strauss, Ravi A Madan, James L Gulley
Frontiers in Oncology|June 17, 2022
Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and ToxicityBrendan Sieber, Julius Strauss, Zihai Li, et al.
Experimental Biology and Medicine (Maywood, N.J.)|April 27, 2022
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current statusSofia R Gameiro, Julius Strauss, James L Gulley, et al.
BMC Cancer|June 6, 2019
Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case reportMichael A Cardis, Hong Jiang, Julius Strauss, et al.
Pharmacogenomics|December 11, 2020
Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in <i>DPYD</i>Tristan M Sissung, Lisa Cordes, Cody J Peer, et al.
The Journal of Clinical Endocrinology and Metabolism|December 9, 2017
Anti-PD-L1 Treatment Induced Central Diabetes InsipidusChen Zhao, Sri Harsha Tella, Jaydira Del Rivero, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Current Oncology Reports|August 16, 2015
Integrating Immunotherapies in Prostate CancerJulius Strauss, Ravi A Madan
Expert Review of Vaccines|February 19, 2016
Therapeutic vaccines for prostate cancer: recent advances and future directionsJulius Strauss, Ravi A Madan
Anticancer Research|January 2, 2016
Using Epigenetic Therapy to Overcome Chemotherapy ResistanceJulius Strauss, William D Figg
Cancer Biology & Therapy|June 10, 2015
Evaluating immune responses after sipuleucel-T therapyJulius Strauss, Ravi A Madan, William D Figg
Expert Opinion on Biological Therapy|March 25, 2016
Considerations for the combination of anticancer vaccines and immune checkpoint inhibitorsJulius Strauss, Ravi A Madan, James L Gulley
Frontiers in Oncology|June 17, 2022
Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and ToxicityBrendan Sieber, Julius Strauss, Zihai Li, et al.
Experimental Biology and Medicine (Maywood, N.J.)|April 27, 2022
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current statusSofia R Gameiro, Julius Strauss, James L Gulley, et al.
BMC Cancer|June 6, 2019
Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case reportMichael A Cardis, Hong Jiang, Julius Strauss, et al.
Pharmacogenomics|December 11, 2020
Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in <i>DPYD</i>Tristan M Sissung, Lisa Cordes, Cody J Peer, et al.
The Journal of Clinical Endocrinology and Metabolism|December 9, 2017
Anti-PD-L1 Treatment Induced Central Diabetes InsipidusChen Zhao, Sri Harsha Tella, Jaydira Del Rivero, et al.
Pageof 4